5-HT1B Agonists - Pipeline Insight, 2024

This “5-HT1B Agonists - Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in 5-HT1B Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

5-HT1B Agonists: Understanding

5-HT1B Agonists: Overview

5-hydroxytryptamine receptor 1B also known as the 5-HT1B receptor is a protein that in humans is encoded by the HTR1B gene. The 5-HT1B receptor is a 5-HT receptor subtype. 5-HT1B receptors are widely distributed throughout the central nervous system with the highest concentrations found in the frontal cortex, basal ganglia, striatum, and the hippocampus. The function of the 5-HT1B receptor differs depending upon its location. In the frontal cortex, it is believed to act as a terminal receptor inhibiting the release of dopamine. In the basal ganglia and the striatum, evidence suggests 5-HT signaling acts on an autoreceptor, inhibiting the release of serotonin and decreasing glutamatergic transmission by reducing miniature excitatory postsynaptic potential (mEPSP) frequency, respectively. In the hippocampus, a recent study has demonstrated that activation of postsynaptic 5-HT1B heteroreceptors produces a facilitation in excitatory synaptic transmission which is altered in depression. When the expression of 5-HT1B in human cortex was traced throughout life, significant changes during adolescence were observed, in a way that is strongly correlated with the expression of 5-HT1E.

The serotonin receptor 5-HT1B is widely expressed in the central nervous system and has been considered a drug target in a variety of cognitive and psychiatric disorders. The anti-inflammatory effects of 5-HT1B agonists may present a promising approach for Alzheimer’s disease (AD) treatment. The evidence outlined range from animal models of disease, effects of 5-HT1B receptor agonists and antagonists, case-control studies of 5-HT1B receptor binding postmortem and in vivo, with positron emission tomography, to clinical studies of 5-HT1B receptor effects of established treatments for MDD. Low 5-HT1BR binding in limbic regions has been found in MDD patients. When 5-HT1BR ligands are administered to animals, 5-HT1BR agonists most consistently display antidepressant-like properties, though it is not yet clear how 5-HT1BR is best approached for optimal MDD treatment.

“5-HT1B Agonists - Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the 5-HT1B Agonists pipeline landscape is provided which includes the disease overview and 5-HT1B Agonists treatment guidelines. The assessment part of the report embraces, in depth 5-HT1B Agonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, 5-HT1B Agonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence 5-HT1B Agonists R&D. The therapies under development are focused on novel approaches to treat/improve 5-HT1B Agonists.

5-HT1B Agonists Emerging Drugs Chapters

This segment of the 5-HT1B Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

5-HT1B Agonists Emerging Drugs

• STS-101: Satsuma Pharmaceuticals

STS101 (dihydroergotamine mesylate (DHE) nasal powder) for the acute treatment of Serotonin 1B Receptor Agonists is Satsuma Pharmaceuticals’ lead product candidate. Both STS101 dosage strengths were well-tolerated in the EMERGE trial, with low adverse event rates and no serious adverse events reported. Satsuma backed its New Drug Application for STS101, which the FDA accepted in May 2023, with data from the Phase III ASCEND study, which gave more than 10,500 doses of STS101 over 18 months to 446 enrolled patients. In January 2024, the FDA rejected Satsuma Pharmaceuticals’ investigational dihydroergotamine nasal powder product STS101 for the treatment of acute migraine. The regulator’s Complete Response Letter (CRL) pointed to problems with STS101’s chemistry, manufacturing and controls. Satsuma will discuss the rejection with the FDA, building toward a resubmission for the nasal drug.

• JM-010: Contera Pharma

JM-010 is developed based on a poly-pharmacological approach to treat or prevent dyskinesia in Parkinson's disease. JM-010 combines the synergistic efficacy of two known drugs in a proprietary formulation. This will provide efficacy reducing involuntary movement without adverse effects. JM-010 has shown very convincing efficacy in preclinical and in Phase IIa cPoC. Based in the data JM-010 should provide a safe and efficacious treatment of dyskinesia in Parkinson's disease. It is currently in Phase II stage of development and is being developed by Contera Pharma.

5-HT1B Agonists: Therapeutic Assessment

This segment of the report provides insights about the different 5-HT1B Agonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in 5-HT1B Agonists

There are approx. 3+ key companies which are developing the therapies for 5-HT1B Agonists. The companies which have their 5-HT1B Agonists drug candidates in the most advanced stage, i.e. Phase II include, Contera Pharma.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

5-HT1B Agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

5-HT1B Agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses 5-HT1B Agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging 5-HT1B Agonists drugs.

5-HT1B Agonists Report Insights

• 5-HT1B Agonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

5-HT1B Agonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing 5-HT1B Agonists drugs?
• How many 5-HT1B Agonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of 5-HT1B Agonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the 5-HT1B Agonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for 5-HT1B Agonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Contera Pharma
• Satsuma Pharmaceuticals

Key Products

• JM-010
• STS-101

This product will be delivered within 2 business days.